KRAS and cancer: Studies show that 88% of serous BOTs are presented withKRAS orBRAF mutations, suggesting their importance in developing SBOTs.71,100 In mucinous BOT (MBOT),KRAS mutations are reported to be at a higher incidence level of 92.3%.89RAS mutation, along withERBB2 andBRAF mutations, can activate the MAPK pathway, ultimately leading to cell proliferation and cancer progression.145 Ohnishi and his group have identifiedKRAS mutations in 43.8% of MOC cases.